<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533674</url>
  </required_header>
  <id_info>
    <org_study_id>PM60184-A-003-14</org_study_id>
    <secondary_id>PM60184-A-003-14</secondary_id>
    <secondary_id>2014-002943-16</secondary_id>
    <nct_id>NCT02533674</nct_id>
  </id_info>
  <brief_title>Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open-label, dose-ranging, uncontrolled phase I study with escalating doses of
      PM060184 in combination with gemcitabine in selected patients with advanced solid tumors.

      The study objectives are:

      To determine the MTD and the RD of PM060184 in combination with gemcitabine in selected
      patients with advanced solid tumors.

      To characterize the safety profile and feasibility of this combination in this study
      population.

      To characterize the pharmacokinetics of this combination and to detect major drug-drug PK
      interactions.

      To obtain preliminary information on the clinical antitumor activity of this combination.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities</measure>
    <time_frame>From the start of treatment to the end of cycle one which are 3 weeks</time_frame>
    <description>Dose Limiting Toxicities will be listed and their incidence summarized by primary system organ class, worst grade based on CTCAE version 4.03 and type of Adverse Event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>days 1 and 2 of cycles 1]. Patients included at the RD will be additionally evaluated on cycle 2 at the same time points</time_frame>
    <description>Pharmacokinetics (PK) of PM060184, Gemcitabine and gemcitabine 2,2 -difluorodeoxyuridine (dFdU) will be evaluated during days 1 and 2 of cycle 1 at 10 time points: at baseline, just before end of infusion (EOT), then 10 min, 25 min, 40 min, 1.10 hs, 2.10 hs, 3.10 hs, 5.10 hs and 24 hs after the EOT .
Pk analysis will be calculated using Non- Compartmental- Analysis (NCA) and population methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve (AUC)</measure>
    <time_frame>days 1 and 2 of cycles 1]. Patients included at the RD will be additionally evaluated on cycle 2 at the same time points</time_frame>
    <description>Pharmacokinetics (PK) of PM060184, Gemcitabine and gemcitabine 2,2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume of distribution based on the terminal half-life (Vz)</measure>
    <time_frame>days 1 and 2 of cycles 1]. Patients included at the RD will be additionally evaluated on cycle 2 at the same time points</time_frame>
    <description>Pharmacokinetics (PK) of PM060184, Gemcitabine and gemcitabine 2,2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance (CL)</measure>
    <time_frame>days 1 and 2 of cycles 1]. Patients included at the RD will be additionally evaluated on cycle 2 at the same time points</time_frame>
    <description>Pharmacokinetics (PK) of PM060184, Gemcitabine and gemcitabine 2,2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume of distribution at steady state (Vss)</measure>
    <time_frame>days 1 and 2 of cycles 1]. Patients included at the RD will be additionally evaluated on cycle 2 at the same time points</time_frame>
    <description>Pharmacokinetics (PK) of PM060184, Gemcitabine and gemcitabine 2,2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of this combination.</measure>
    <time_frame>Baseline, then every 6 weeks, until disease progression or discontinuation an expected overage of 24 weeks</time_frame>
    <description>This includes: response rate evaluated using RECIST V1.1 for most of the selected solid tumors and CHOI criteria and /or EORTC metabolic response criteria for gastrointestinal stromal tumor (GIST), also time related parameters [Progression Free Survival (PFS), Overall Survival and duration of response (DR) using the Kaplan-Meier (KM) method]]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events as a Measure of Safety and Tolerability of PM060184 in combination with gemcitabine</measure>
    <time_frame>from the start of the treatment to the end of the treatment, an expected average of 24 weeks</time_frame>
    <description>Adverse events and their frequency, duration and severity, physical examination, laboratory parameters, vital signs and ECG change monitoring as determined based on CTCAE (Common Toxicity Criteria for Adverse Effects) 4.03</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Polymorphism analysis</measure>
    <time_frame>blood sample obtained pre-infusion of Cycle 1 day 1</time_frame>
    <description>Polymorphism analysis (pharmacogenetic) for presence or absence of germline mutations or polymorphism will be analyzed in leukocyte DNA extracted from a blood sample</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>gemcitabine plus PM060184</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine plus PM060184</intervention_name>
    <arm_group_label>gemcitabine plus PM060184</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntarily signed and dated written informed consent prior to any specific study
             procedure.

          2. Age ≥ 18 years.

          3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤ 1 (see APPENDIX
             1).

          4. Life expectancy ≥ 3 months.

          5. Patients with a histologically/cytologically confirmed diagnosis of advanced disease
             of any of the following tumors that progressed to standard therapy or for whom no
             standard therapy exists:

               -  Breast cancer non-candidate for hormone therapy alone.

               -  Epithelial ovarian cancer (including primary peritoneal disease and/or fallopian
                  tube carcinomas and/or endometrial adenocarcinomas).

               -  Locally advanced or metastatic head and neck cancer.

               -  Non-small cell lung cancer (NSCLC).

               -  Germ cell tumors (GCTs).

               -  Biliary tract adenocarcinoma.

               -  Adenocarcinoma or carcinoma of unknown primary site (UKPS).

               -  Cervix carcinoma.

               -  Gastrointestinal stromal tumor (GIST).

               -  Urothelial cancer.

          6. Expansion cohort at the RD:

             All patients must have:

               -  Measurable disease according to RECIST v.1.1 (or Choi criteria and/or EORTC
                  metabolic response criteria for solid tumors, in the case of GIST); or

               -  Evaluable disease by serum markers in the case of ovarian cancer [Gynecologic
                  Cancer Intergroup (GCIG) specific criteria]; and

               -  Documented disease progression during or immediately after last therapy according
                  to any of the aforementioned criteria.

          7. Wash-out periods: at least three weeks since the last anticancer therapy, including
             radiation therapy (RT) in more than 35% of the bone marrow; at least three weeks since
             the last biological/investigational therapy [excluding monoclonal antibodies (MAbs)];
             at least four weeks since the last MAb-containing therapy; and at least six weeks
             since nitrosoureas and mitomycin C (systemic). In the case of hormonesensitive breast
             cancer progressing while on hormone therapy, the latter must be either stopped up to
             one week before or continued without changes during the trial.

          8. Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤ 7 days before
             inclusion in the study):

               -  Platelet count ≥ 100 x 109/l, hemoglobin ≥ 9.0 g/dl and ANC ≥ 1.0 x 109/l.

               -  AST and ALT ≤ 3.0 x ULN, independently of the presence of liver metastases.

               -  AP ≤ 2.5 x ULN (≤ 5 x ULN if disease-related).

               -  Total bilirubin ≤ 1.5 x ULN.

               -  International Normalized Ratio (INR) &lt; 1.5 (except if patient is on oral
                  anticoagulation therapy).

               -  Calculated creatinine clearance (CrCl) ≥ 50 ml/minute (using Cockcroft and
                  Gault's formula; see APPENDIX 2).

               -  Albumin ≥ 2.5 g/dl.

          9. Recovery to grade ≤ 1 from any AE derived from previous treatment (excluding alopecia
             and/or cutaneous toxicity and/or asthenia).

         10. Left ventricular ejection fraction (LVEF) by echocardiography (ECHO) or multiplegated
             acquisition (MUGA) within normal range (according to institutional standards).

         11. Women of childbearing potential must have a negative serum or urine pregnancy test
             before study entry. Both women and men must agree to use a medically acceptable method
             of contraception throughout the treatment period and for six weeks after
             discontinuation of treatment. Acceptable methods of contraception include intrauterine
             device (IUD), oral contraceptive, subdermal implant and/or double barrier.

        Exclusion Criteria:

          1. Concomitant diseases/conditions:

               -  History or presence of unstable angina, myocardial infarction, congestive heart
                  failure, or clinically significant valvular heart disease within last year.

               -  Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing
                  treatment.

               -  Known chronic active hepatitis or cirrhosis

               -  Active uncontrolled infection [i.e., antibiotic, antifungal or antiviral
                  intervention indicated or surgical procedure (i.e., pleural or deep abscess
                  drainage) conducted within 15 days prior to inclusion].

               -  Known human immunodeficiency virus (HIV) infection.

               -  Current or prior history of grade ≥ 2 peripheral sensory and/or motor neuropathy.

               -  Prior treatment with oxaliplatin.

               -  Limitation of the patient's ability to comply with the treatment or follow-up
                  protocol.

               -  Any other major illness that, in the Investigator's judgment, will substantially
                  increase the risk associated with the patient's participation in this study.

          2. Symptomatic, progressive or corticosteroids-requiring documented brain metastases or
             leptomeningeal disease involvement.

          3. Men or women of childbearing potential who are not using an effective method of
             contraception as previously described; women who are pregnant or breast feeding.

          4. Patients who have had RT in more than 35% of the bone marrow.

          5. Treatment with any investigational product within 30 days before the first infusion.

          6. Prior treatment with PM060184.

          7. Prior treatment with gemcitabine-containing therapy for advanced disease (adjuvant
             therapy is allowed, provided not more than six cycles were administered and relapse
             occurred more than six months after the last drug administration), and/or:

               -  Patients who have previously discontinued gemcitabine-containing regimens due to
                  gemcitabine-related toxicity.

          8. Known hypersensitivity to gemcitabine or any component of the formulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cinthya Coronado, MD</last_name>
    <email>clinicaltrials@pharmamar.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2015</study_first_submitted>
  <study_first_submitted_qc>August 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

